logo
logo

Endeavor BioMedicines Launches with $62 Million Series A Financing and Mission to Reverse the Course of Devastating Pulmonary Disease

Jan 07, 2021•over 4 years ago

Amount Raised

$62 Million

Round Type

series a

San Diego

Description

Endeavor BioMedicines, a biotechnology company developing new treatments targeting the underlying causes of pulmonary fibrosis, today announced it has raised $62 million in a Series A financing. The round was led by Omega Funds, Longitude Capital and Endeavor’s management. Proceeds from the financing will be used to advance taladegib, an inhibitor of the Hedgehog pathway, into two Phase 2 clinical studies for the treatment of idiopathic pulmonary fibrosis (IPF) in 2021.

Company Information

Company

Endeavor Bio Medicines

Location

San Diego, California, United States

About

Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis. The company is developing taladegib, a small-molecule inhibitor of the Hedgehog signaling pathway, that is being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). By targeting this underlying cause of disease, taladegib has the potential to halt and even reverse IPF. Endeavor is supported by leading investors Omega Funds and Longitude Capital. More information is available at www.endeavorbiomedicines.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech